16 completed, 3 unknown, 2 terminated, 1 no longer available. 15 Phase 1, 12 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 15 | Completed 12, Unknown 2, Terminated 1 |
| Phase 2 | 12 | Completed 8, Terminated 2, Unknown 2 |
| Phase 3 | 1 | Completed 1 |
Follow Tracon Pharmaceuticals Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma YH001, Envafolimab, Doxorubicin - Advanced Sarcoma, Metastatic Sarcoma | Phase 1 / Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 15 | 2022-11-14 | 2023-09-21 |
| ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma Envafolimab, Ipilimumab - Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma | Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 207 | 2020-12-09 | 2024-05-17 |
| Study of TJ004309 in Combination With Atezolizumab (Tecentriq®) in Patients With Advanced or Metastatic Cancer TJ004309, Atezolizumab - Solid Tumor, Metastatic Cancer | Phase 1 | Unknown | Tracon Pharmaceuticals Inc. | 36 | 2019-07-16 | 2022-04-01 |
| Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC Carotuximab (TRC105), OPDIVO - Carcinoma, Non-Small-Cell Lung | Phase 1 | Completed | Tracon Pharmaceuticals Inc. | 11 | 2017-11-09 | 2020-06-24 |
| Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients TRC253 - Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate | Phase 1 / Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 72 | 2017-05-23 | 2021-04-23 |
| Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma TRC105, Votrient - Advanced Angiosarcoma | Phase 3 | Completed | Tracon Pharmaceuticals Inc. | 128 | 2017-02-13 | 2020-05-12 |
| Trial of TRC105 and Sorafenib in Patients With HCC Carotuximab (TRC105), Sorafenib - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 27 | 2016-11-01 | 2020-07-17 |
| Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) TRC105, Bevacizumab - Gestational Trophoblastic Neoplasia, Choriocarcinoma | Phase 2 | Terminated | Tracon Pharmaceuticals Inc. | 3 | 2016-03-01 | 2019-07-23 |
| A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer TRC105 - Lung Cancer | Phase 1 | Completed | University of Alabama at Birmingham | 16 | 2015-11-02 | 2021-06-28 |
| Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC TRC105 - Non Small Cell Lung Cancer | Phase 1 | Completed | Tracon Pharmaceuticals Inc. | 15 | 2015-09-01 | 2019-10-28 |
| Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer Letrozole, Everolimus, TRC105 - Breast Cancer | Phase 1 / Phase 2 | Completed | University of Alabama at Birmingham | 15 | 2015-02-01 | 2026-02-06 |
| TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma TRC105, Bevacizumab - Choriocarcinoma | Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 2 | 2015-01-01 | 2019-06-11 |
| A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma TRC105 and Pazopanib - Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 111 | 2013-12-10 | 2020-05-20 |
| Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma TRC105 and Axitinib, Axitinib - Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Tracon Pharmaceuticals Inc. | 173 | 2013-03-08 | 2020-10-19 |
| A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma TRC105, Bevacizumab - Glioblastoma, Glioblastoma Multiforme | Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 22 | 2012-05-01 | 2019-06-12 |
| Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Carotuximab (TRC105) - Recurrent Ovarian Cancer, Fallopian Tube Carcinoma | Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 23 | 2011-07-01 | 2019-03-05 |
| Open Label Dose-Finding Study of TRC105 Plus Capecitabine for Metastatic Breast Cancer TRC105, Capecitabine - Metastatic Breast Cancer | Phase 1 / Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 19 | 2011-06-01 | 2019-03-18 |
| Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated TRC105 and Bevacizumab - Adult Solid Tumor | Phase 1 | Completed | Tracon Pharmaceuticals Inc. | 38 | 2011-04-01 | 2018-12-05 |
| Study of TRC102 in Combination With Pemetrexed in Cancer Patients TRC102 + pemetrexed - Neoplasm | Phase 1 | Completed | Tracon Pharmaceuticals Inc. | 28 | 2008-06-01 | 2010-09-10 |
| Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer TRC105 chimeric anti-CD105 antibody - Cancer, Neoplasm Metastasis | Phase 1 | Completed | Tracon Pharmaceuticals Inc. | 51 | 2007-12-01 | 2012-03-05 |
Showing 20 of 22. Sign in to see all of them.
Neoplasm Metastasis (3) · Neoplasms (3) · Sarcoma (3) · Breast Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (2) · Choriocarcinoma (2) · Hemangiosarcoma (2) · Adenocarcinoma (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Renal Cell (1) · Chondrosarcoma (1) · Dermatofibrosarcoma (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Fallopian Tube Neoplasms (1) · Gestational Trophoblastic Disease (1)
carotuximab (15) · Bevacizumab (6) · pazopanib (3) · Axitinib (2) · Capecitabine (2) · envafolimab (2) · Androgen Receptor Antagonists (1) · Carboplatin (1) · Doxorubicin (1) · Everolimus (1) · Ipilimumab (1) · Letrozole (1) · Nivolumab (1) · Paclitaxel (1) · Pemetrexed (1)
United States (21) · United Kingdom (3) · Austria (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Poland (1) · Spain (1)
Charles Theuer, MD (5) · Charles Theuer, MD, PhD (5) · Charles Theuer, MD PhD (3) · Charles P Theuer, MD (2) · James Freddo, MD (2) · Bryan Leigh, MD (1) · Bryan R Leigh, MD (1) · Erica Stringer-Reasor, M.D. (1) · Erica Stringer-Reasor, MD (1) · Francisco Robert, MD (1)
PMID 21034418, PMID 23054206, PMID 30190302, PMID 30357394, PMID 35357396, PMID 36735117